This article was originally published in The Gray Sheet
Board authorizes repurchase of up to 1 mil. shares of common stock. Separately, the Atlanta-based maker of human tissue implantable devices reported a 10% increase in third quarter revenues to $16 mil. Net income, excluding effects of the sale of the firm's Ideas for Medicine business, was up 31% to $1.9 mil. Including the sale, net income was up 118.7% to $3.2 mil
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.